drugset
Drugs / rPA102
last change Jul 2005 re-read 3 minutes ago

rPA102

Vaccine

Developed for
anthrax infection
Investigated by
VaxGen · Centers for Disease Control and Prevention · National Institute of Allergy and Infectious Diseases (NIAID) · National Institutes of Health (NIH)

Trials 2

today NCT00100724 · Ph 2 NCT00103467 · Ph 1
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00103467 Jun 2003 → ? anthrax infection VaxGen Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00100724 Apr 2004 → Jul 2005 anthrax infection VaxGen Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as rPA-102 “A Phase 2 Multi-Center, Randomized Dose-Finding Trial of rPA-102 Vaccine in Healthy Adult Volunteers” NCT00100724 ↗
2

NCT00103467 ↗

NCT00100724 ↗
Modality Vaccine “rPA-102 Vaccine” NCT00100724 ↗
Route Intramuscular “given intramuscularly” NCT00100724 ↗